Evaluating the Clinical Benefit of Post-Transplant DNA Methyltransferase Inhibitor (DNMTi) Maintenance in MDS/AML
Lindsay Orton(Vanderbilt University), Kathryn A. Culos(Vanderbilt University Medical Center), Reena Jayani(Vanderbilt University Medical Center), Adetola A. Kassim(Vanderbilt University), Brian G. Engelhardt(Vanderbilt University Medical Center), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Tae Kon Kim(Vanderbilt University), Katie S. Gatwood(Vanderbilt University Medical Center), Bipin N. Savani(Vanderbilt University Medical Center), Brendan L. Mangan, Heidi Chen(Vanderbilt University Medical Center), Michael Byrne(Breast Cancer Research Foundation)
Cited by 0
Related Papers
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer
|JAMA Oncology|2021|464
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|435
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
|Biology of Blood and Marrow Transplantation|2015|409